pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
NOVARTIS · news · pharmadog
← back to NOVARTIS
News mentioning NOVARTIS
367
stories
Sep 8, 26
Novartis RNA drug falls short in rare muscle disease study
biopharma dive
Sep 8, 26
AstraZeneca’s SERD pill overcomes adcomm defeat to win FDA nod in breast cancer
biospace
Sep 8, 26
Novartis’ $12B Avidity acquisition hits Phase 3 speedbump as dystrophy drug disappoints
biospace
Sep 8, 26
Novartis’ cholesterol-lowering medicine fails Phase 3, clouding Lp(a) horizons
biospace
Sep 8, 26
STAT+: Inhibrx claims first win for long-sought immunotherapy target
stat
Sep 8, 26
STAT+: Roivant lung disease drug hits mid-stage study goals
stat
Sep 8, 26
Updated: Novartis sinks after second disastrous trial failure, this time of Avidity-acquired drug
endpoints
Sep 8, 26
STAT+: Neuromuscular drug from Novartis fails in key study, adding to pressure on company
stat
Sep 8, 26
AI will only revolutionize drug discovery and development if we play to its strengths
biospace
Sep 8, 26
Novartis stock slides as centerpiece of $12B Avidity buyout flunks ‘crucial’ phase 3 test
fiercebiotech
Sep 8, 26
Recon: FDA approves AZ’s breast cancer drug over negative adcomm vote; Novartis sees setbacks for drugs targeting cholesterol, m...
raps
Sep 7, 26
Novartis' Phase 3 pelacarsen study miss raises the stakes for Amgen, Lilly
endpoints
Sep 7, 26
STAT+: Novo Nordisk stops two cardiovascular trials of drug aimed at lowering inflammation
stat
Sep 5, 26
Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines
biopharma dive
Sep 5, 26
CAR-T deaths prompt halt by Novartis; Eli Lilly’s 13th acquisition of 2026; and more
endpoints
Sep 4, 26
STAT+: Novartis’ experimental cardiovascular drug fails a pivotal study
stat
Sep 4, 26
Novartis Lp(a) drug fails to lower cardiovascular risk in closely watched ph. 3 trial
fiercebiotech
Sep 4, 26
This week in charts: China deals, stock flatlines and Lilly’s M&A spree
biopharma dive
Sep 4, 26
STAT+: We’re reading about a Bristol CAR-T trial pause, Pfizer offloading a shelved candidate, and more
stat
Sep 3, 26
Novartis' drug delivery deal with Alteogen; More worker cuts at Cellares
endpoints
Sep 3, 26
Pfizer shares ADC rights with Medicus; RevMed updates lung cancer data
endpoints
Sep 3, 26
STAT+: Fauci speaks, and writes
stat
Sep 3, 26
STAT+: We’re reading about an Ultragenyx failure, RevMed for lung cancer, and more
stat
Sep 3, 26
The hidden scale-out problem behind CAR-T’s growth
biopharma dive
Sep 3, 26
Opinion: STAT+: A surprising bright spot at the FDA on regulating unproven stem cells
stat
Sep 2, 26
STAT+: Ultragenyx drug to treat Angelman syndrome, a rare disease, fails late-stage trial
stat
Sep 2, 26
Novartis CAR-T deaths raise questions over acceptable autoimmune risk
endpoints
Sep 2, 26
Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts
biopharma dive
Sep 2, 26
Novartis telegraphs 130 job cuts amid biologics rethink in Switzerland
fiercebiotech
Sep 2, 26
STAT+: ARPA-H funds biotechs working on custom RNA therapies
stat
← prev
page 7 of 13
next →
